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Abstract
Native osteochondral repair is often inadequate due to the inherent properties of the tissue and
current clinical repair strategies can result in healing with a limited lifespan and donor site
morbidity. This work investigates the use of polymeric gene therapy to address this problem by
delivering DNA encoding for transcription factors complexed with the branched
poly(ethylenimine)-hyaluronic acid (bPEI-HA) delivery vector via a porous oligo[poly(ethylene
glycol) fumarate] (OPF) hydrogel scaffold. To evaluate the potential of this approach, a bilayered
scaffold mimicking native osteochondral tissue organization was loaded with DNA/bPEI-HA
complexes. Next, bilayered implants either unloaded or loaded in a spatial fashion with bPEI-HA
and DNA encoding for either Runt-related transcription factor 2 (RUNX2) or SRY (sex
determining region Y)-box 5, 6, and 9 (the SOX trio), to generate bone and cartilage tissues
respectively, were fabricated and implanted in a rat osteochondral defect. At 6 weeks post-
implantation, micro-computed tomography (micro-CT) analysis and histological scoring were
performed on the explants to evaluate the quality and quantity of tissue repair in each group. The
incorporation of DNA encoding for RUNX2 in the bone layer of these scaffolds significantly
increased bone growth. Additionally, a spatially loaded combination of RUNX2 and SOX trio
DNA loading significantly improved healing relative to empty hydrogels or either factor alone.
Finally, the results of this study suggest that subchondral bone formation is necessary for correct
cartilage healing.
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Osteochondral injuries are an area of in depth research due to the inadequacy of native
healing and the limited lifespan and quality of conventional treatments.1, 2 Cartilage tissue is
often limited in its ability to regrow due to its heavy dependence on appropriate extracellular
matrix generation and lack of blood flow. Tissue engineering is one area of research that
could address these current inadequacies and provide an improved therapy for osteochondral
injuries.
In particular, gene delivery is one developing and promising option for osteochondral injury
repair in the context of tissue engineering. Gene delivery has the ability to utilize often
otherwise unusable therapeutic proteins by directly inducing their expression within the cells
of a target tissue through delivery of nucleotides into those cells. Osteochondral and
chondral tissues are especially promising for polymeric gene delivery approaches because of
the limited blood flow to the region, which can cause problems in DNA polymer complex
delivery, and the potential for the delivered genes to induce differentiation of infiltrated
mesenchymal stem cells (MSCs). By using transcription factors that regulate many
downstream proteins, gene delivery could be capable of inducing more physiologically
correct differentiation in target cells. This work utilized the transcription factors Runt-
related transcription factor 2 (RUNX2), or CBFA1, which has been shown to induce
osteogenic differentiation3, and SRY (sex determining region Y)-box 5, 6, and 9 (the SOX
trio), which has been shown to induce chondrogenic differentiation.4, 5
To deliver these transcription factors into the cell, a gene delivery vector is needed. This
work utilizes branched poly(ethylenimine) (bPEI), a commonly used polymer for gene
delivery, modified with hyaluronic acid (HA). The resulting product, bPEI-HA has been
shown to mitigate many of the negative effects associated with bPEI, such as its high
cytotoxicity, while improving transfection efficiency and potentially providing cellular
targeting through hyaladherins on the cell’s surface. 6–9
Studies have examined the role of the SOX trio and RUNX2 in chondrogenesis and
osteogenesis both separately and in combination with each other and other bioactive
factors.5, 10 It has been shown that the SOX trio is capable of inducing chondrogenic
differentiation in target cells both in vitro and in vivo11 and that this combination of
transcription factors has the potential to do so in vitro without the use of inductive factors.49
Further, when cells transduced with the SOX trio were implanted into a rat osteochondral
defect for 8 weeks, they were found to promote defect healing.12 In other studies, PLGA
scaffolds loaded with bPEI and bPEI based vectors complexed with DNA encoding for the
SOX trio have been shown capable of inducing cartilage growth in vivo and in vitro.13, 14
RUNX2 has also been shown to be an effective driver of differentiation.15 When DNA
encoding for RUNX2 is transduced into stem cells which are seeded onto scaffolds and
implanted into animals, substantially more bone can be grown than in control
situations.16–18 Additionally, when adenoviral RUNX2 is immobilized on a scaffold, it is
still capable of increasing osteogenic differentiation.19 One important consideration with
relation to this study is that it has been shown that these two groups, the SOX trio and
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RUNX2, have inhibitory effects on each other when applied to the same cell population in
vitro and in vivo.20, 21 In fact, it has been shown that SOX9 is dominant and inhibitory to
RUNX2 in vivo.22 This work investigates the hypothesis that by spatially loading these two
complexes to mimic native tissues, distinct zones of osteogenesis and chondrogenesis can be
achieved without negative interactions.
Oligo[poly(ethylene glycol) fumarate] (OPF) is a promising hydrogel for use in tissue
engineering, including for applications involving bone23 and cartilage24 tissue growth, and
combined osteochondral repair.25–28 This hydrogel is formed by crosslinking a linear
polyester formed by condensing poly(ethylene glycol) (PEG) and fumaryl chloride. The
mesh size of the crosslinked hydrogel can be controlled by varying the molecular weight of
the incorporated PEG chains, and higher concentrations of fumarate ester groups inside the
polymer result in higher crosslinking and more points for degradation.29, 30 OPF has
numerous favorable biological properties including being biocompatible, bioinert, and non-
immunogenic, in addition to having inert degradation products.31
OPF is attractive as a delivery vehicle for a number of reasons. First, it is a synthetic rather
than natural polymer and therefore offers tunable properties such as mesh size, degradation
rate, and mechanical properties to allow for modification for a specific application.
Moreover, it is attractive for use with plasmid DNA and other nucleotides because it can be
crosslinked under physiologic conditions without harsh processing that could degrade or
injure the genetic material.27 The inherent hydrophilicity of the system and hydrogel
fabrication process results in an ability to entrap large concentrations of polymer/DNA
complexes at relatively high loading efficiencies.26–28 Furthermore, OPF has been used to
deliver DNA and bPEI in previous work by either direct loading of complexes or by loading
complex laden gelatin particles.26–28 These studies have explored release of plasmid DNA
from OPF hydrogels both in vitro and in vivo, as well as directly from the hydrogel or from
an incorporated carrier. When incorporated directly into the hydrogel during fabrication,
release of plasmid/polymer complexes was found to have a favorable profile lasting several
weeks.28
In the present study, we hypothesize that the regeneration of bone and cartilage tissue will
be enhanced by the delivery of bPEI-HA and DNA encoding for transcription factors in a
porous OPF hydrogel scaffold. The inclusion of carboxymethyl cellulose (CMC) as a
porogen in the OPF scaffold is also expected to increase tissue distribution inside of the
scaffolds by generating voids inside the scaffold which cells can migrate into. Additionally,
the dual delivery of RUNX2 and the SOX trio is expected to improve the quality and
amount of bone and cartilage generation within the defects. To examine these hypotheses,
composite scaffolds were implanted in a rat osteochondral defect for 6 weeks and analyzed
using micro-CT and histology.
2. MATERIALS AND METHODS
2.1 In Vivo Experimental Design
Composite scaffolds consisting of OPF, CMC, and bPEI-HA/DNA complexes were
examined in vivo for their ability to generate tissue in a rat knee osteochondral defect model.
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Groups for this study were designed to examine the interactions and efficacy of the use of
DNA encoding for the transcription factors SOX 5, SOX 6, and SOX 9 (the SOX trio), and
RUNX2 delivered with bPEI-HA. The groups examined here are summarized below in
Table 1 and included a material control, RUNX2 DNA only, and SOX trio DNA only in
order to identify the effects of each component individually as well as a combination group
used to identify combinatory effects of RUNX2 and the SOX trio.
2.2 Assembly of bPEI-HA/DNA Complexes
Branched PEI-HA was synthesized as previously described,6, 9 using a reductive amination
reaction to directly conjugate the hyaluronic acid fragments (6.4kDa) (LifeCore Biomedical,
Chaska, MN) to the primary amines of the bPEI (Sigma-Aldrich, St. Louis, MO). The
structure was verified with 1H NMR to ensure correct conjugation as has been described
previously.6, 9
Plasmid DNA encoding for RUNX2, SOX5, SOX6, and SOX9 (Origene, Rockville, MD)
was expanded using DNA expansion kits according to the manufacturer’s instructions
(Qiagen, Venlo, Netherlands), collected, and used directly. For loading into hydrogels,
bPEI-HA and DNA were combined drop wise in a constant 7.5:1 Nitrogen:Phosphate (N:P)
ratio and allowed to complex in ultrapure (type 1) water (Super-Q Water Purification
System, EMD Millipore, Billerica, MA) at room temperature for 30 min before use. After
complexation, complexes were lyophilized for 48 hrs in preparation for use in hydrogel
loading.
2.3 OPF Synthesis and Characterization
Synthesis of OPF was performed as previously described.29, 32, 33 Briefly, anhydrous
dichloromethane (EMD, Billerica, MA) was obtained through refluxing in the presence of
calcium hydride (Sigma Aldrich, St. Louis, MO) followed by distillation. Anhydrous PEG
(Mn = 9.3 ± 0.1 kDa, Mw = 13.1 ± 0.1 kDa, n =3) (Sigma Aldrich, St. Louis, MO) was
generated through distillation in toluene (Fisher Scientific, Waltham, MA) and then added to
the anhydrous dichloromethane. Triethylamine (Sigma Aldrich, St. Louis, MO) and fumaryl
chloride (Acros, Geel, Belgium) were added to this PEG solution drop wise and the reaction
was incubated for 2 days. Purification was then performed and characterization of the
product was performed through analysis with gel permeation chromatography using PEG
standards and 1H NMR to verify correct structure and fumarate PEG ratios as previously
described.29, 32, 33 The OPF used in this work has a Mn of 19.8± 0.3 kDa and a Mw of 89.9 ±
3.9 kDa (n = 3).
2.4 Composite Scaffold Fabrication
Scaffolds for use in the studies described below were composites consisting of an OPF
hydrogel crosslinked around CMC particles (US Pharmacopeia Grade Lot #YD0567,
Spectrum Chemicals and Products, Gardena, CA) up to 100 μm in diameter. For fabrication
of the composites, OPF and poly(ethylene glycol)-diacrylate (PEGDA) (MW = 3,400 Da,
Laysan Bio, Arab, AL) were first dissolved in PBS [2:1 OPF:PEG-DA weight ratio, 38%
w/v gel in water]. Immediately before OPF crosslinking was initiated, dried DNA/bPEI-HA
complexes were suspended in the OPF/PEGDA solution. For each layer, a DNA
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concentration of 6.2 mg/ml (after swelling) was maintained, which corresponds to levels
previously shown to elicit a response in vivo.34 Once dispersed, ammonium persulfate (APS)
and N,N,N′,N′-tetramethylethane-1,2-diamine (TEMED) were added to the solution [3.6
mM] and it was vigorously stirred for 30 s. At the end of these 30 s, CMC particles were
added to the mixture and it was stirred for an additional 45 s before being added into custom
poly(tetrafluoroethylene) (PTFE) molds. For bilayered scaffolds, the bottom osteogenic
layer was allowed to crosslink for 3 min in a PTFE mold before addition of another mold
directly on top was filled with crosslinking chondrogenic layer hydrogel. Once the two
layers were stacked, they were allowed to finish crosslinking for 10 min prior to use.
Scaffolds for use in in vitro release and in vivo implantation were fabricated as 8 mm
diameter by 1.2 mm thickness discs which were then punched with a custom punch such that
the final scaffold punch dimensions were 1.2 mm in diameter by 1.2 mm thickness with each
layer having a 0.6 mm thickness. These dimensions correspond to a 1.5 mm diameter by 1.5
mm thickness implant after swelling.
2.5 Surgical Procedure
32 Lewis rats (Charles River Laboratories, Wilmington, MA) 12 weeks of age for skeletal
maturity were used in this study. All manipulations described followed protocols approved
by the Institutional Animal Care and Use Committee at Rice University and published NIH
guidelines for the care and use of laboratory animals have been observed. All implants were
fabricated directly before implantation. Each composite scaffold contained CMC and OPF in
an 1:1 weight ratio during fabrication as well as 8.4 μg DNA per scaffold in the combined
scaffolds (4.2 μg DNA in either the RUNX2 or SOX trio only scaffolds). All animals
survived the surgery and post-operative period with no signs of distress of infection for the
duration of the study.
To complete the surgery, previously established procedures were followed to create defects
in the right femoral condyle of the rat.35, 36 The surgical site was sterilely prepared and a
lateral approach was used to expose the knee joint through blunt dissection. A lateral
parapatellar incision was made and the patella dislocated medially to access the knee. The
joint capsule was then opened and the defect was established along the midline and midway
up the trochlear groove from the knee with a 0.9 mm drill bit and was created with a 1.5 mm
drill bit. The defect was then flushed with saline and filled with the implant prepared as
described above. The patella was then physically relocated and the wound closed in three
layers. Animals were closely monitored for any signs of discomfort.
2.6 In Vivo Tissue Preparation
Six weeks after implantation, animals were anesthetized with 4–5% isofluorane and
euthanized with carbon dioxide. A subsequent bilateral thoracotomy was performed to
ensure death before the treated knees were extracted. The knees were then placed in 10%
neutral buffered formalin for 1 week for fixation. Micro-CT scans were then performed on
all samples before they were decalcified in 5% formic acid for 14 days and dried in an
ethanol gradient from 50–100% (50, 70, 80, 90, 95, 100%) before staining. In vivo animal
samples were analyzed for cartilage and bone generation through micro-CT and histology
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according to guidelines previously established for use in a bilayed osteochondral defect in a
rabbit model.37–40
2.7 Micro-CT Imaging and Analysis
Before decalcification for histology was performed, micro-CT analysis was used to
determine the mineralization as previously described.41 All images were taken with a high
resolution SkyScan-1172 micro-CT imaging system. Samples were oriented so that the axis
of the defect was vertical in the micro-CT chamber. The scanner resolution was set to 10.2
μm/pixel with a voltage of 100 KV and a current of 100 μA. The resolution of the camera
was set to high (1280 × 1024 raw images). The defect was then reconstructed by
backprojecting the raw images in a NRecon CT Reconstruction software package.
1.5 mm diameter, 1.5 mm height volumes of interest were then selected within the
reconstructed images at the site of the defect for each sample. To calculate the percent bone
formation within these volumes of interest, a lower binarization threshold of 45 and upper
binarization threshold of 255 were set to identify bone morphology within the samples. With
these values, percent bone formation within the samples was defined as the bone volume
within the volume of interest divided by the total volume of interest expressed as a
percentage.
2.8 Histology
For histological analysis, the dried samples were embedded in paraffin and sectioned in 6
μm slices. Sections from two locations within the defect (center and medial) were obtained
and stained with hematoxylin and eosin (H&E) and Safranin O/Fast Green. Safranin O was
selected for its ability to stain glycosaminoglycans (GAGs) and give an indication of the
extent of chondrogenesis. 37, 39 Each of these sections was independently analyzed by three
evaluators according to procedures described previously.37, 39 Briefly, the region of the
defect corresponding to the native cartilage thickness was analyzed for cartilage tissue
generation and the lower portion corresponding to native bone was analyzed for bone
regeneration. Osteochondral repair was evaluated using 13 predetermined measures of
regeneration which are listed in Table 2 and cover the quantity and quality of the
regeneration of tissues, scaffold degradation, and integration of new tissues with
surrounding native tissues. It is important to note that while the micro-CT percent bone
formation was calculated digitally, all histological filling scores were completed blindly and
independently by 3 investigators.
2.9 Statistics
Statistical analysis was performed on the data collected for in vitro release and micro-CT
analysis using two-way ANOVA with a priori value of 0.05. Post hoc analysis was
performed via Tukey-Kramer HSD to identify statistical significance (p<0.05) between each
of the groups. Each of the in vivo histological scoring parameters was analyzed using the
Kruskal Wallis test of variance and the Wilcoxon rank sum test for difference of groups with
a significance level of p<0.05. All data are presented as means ± standard deviation, with the
exception of histological results which presented the total number of each score attained for
each group. The in vitro studies had an n of 4 while in vivo studies had a n of 8.
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During the tissue harvest, no signs of gross infection or any other adverse tissue responses
were observed and all animals were ambulatory for the duration of the study.
3.2 Micro-CT
Micro-CT images were taken for each sample and analyzed to determine the percentage of
bone present within the defect volume. There was no significant difference in percent
regenerated bone volume between groups, as shown in Figure 1, but the analysis
demonstrated measureable bone growth in all in vivo study groups with a high percentage
formation of 29.5±8.0% found in the combination treatment group.
3.3 Histology
Histological analysis was performed on the collected sections from the medial edge and the
center of each defect as described above to determine the regeneration and tissue response
within the created defects. Histology was selected as the main metric for tissue generation
rather than gene expression due to the transient nature of expression of genes delivered with
polymeric gene delivery vectors.42 The results for each parameter outlined in Table 2 are
displayed in Figures 2, 3, and 4 and numerous statistical differences were observed.
Representative histological results from the center of each group are included as in Figures
5, 6, 7, and 8.
In all of the groups a portion of the composite scaffold remained in the defect region. The
groups with either an empty hydrogel or with only the SOX trio delivered had significantly
more hydrogel present and significantly less new tissue growth into the defect as seen in
Figures 2, 7, and 8. The combined treatment group had significantly higher tissue filling and
less hydrogel present than all other groups as shown in Figures 2 and 5. Finally, the RUNX2
treatment group statistically fell between the best case combined treatment group and the
more negative Empty and SOX trio only groups for tissue filling and implant degradation as
shown in Figure 2.
For bone growth and quality, the SOX trio only group scored significantly lower in many
cases. For percent filling with bone the SOX trio treatment group grew significantly less
bone than all other test groups as demonstrated in Figures 3 and 7. For subchondral tissue
morphology, the SOX trio scored significantly lower than all groups except for the blank
hydrogels, signifying a poorer quality of the generated tissue. These results can be seen in
the bone excerpts from the representative histological sections, Figures 5–8. While RUNX2
outperformed the SOX trio in bone quality and quantity, it was not significantly different
from the empty gels and scored significantly worse than the combined group which was
significantly better than all other test groups as seen in Figures 3a, 3b, and 5. These
differences also are reflected in the example histological sections. Finally as seen in Figure
3c, there were fewer statistical differences in the bone bonding scoring, but the SOX trio did
score significantly lower than the combined treatment group.
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In the cartilage scoring portion, significant differences were found. For joint surface
regularity and the thickness of the new cartilage shown in Figures 4c and 4d, the combined
treatment group significantly outperformed the SOX trio group, signifying an improvement
in the surface healing of the defect which is clearly seen in the representative histological
sections in Figures 5 and 8. Conversely, for chondrocyte distribution the SOX trio group
was found to have a significantly better distribution than the combined treatment group,
shown in Figure 4e. Similar trends as were found for the bone histological scoring were
present in the cartilage scoring categories which were listed in this paragraph, but did not
achieve levels of significance.
4. DISCUSSION
Composite scaffolds were designed and fabricated to facilitate cellular infiltration and tissue
ingrowth. OPF was selected due to its established ability to support regrowth of cartilage
and bone while remaining non-toxic to target tissues immediately after implantation and
during and after degradation. Additionally, by using a hydrogel, loading of high amounts of
DNA in a spatially bilayered approach was possible while retaining the ability to release the
genetic material and polymer delivery vector simultaneously. Because previous work has
shown that implanting porous hydrogels into a defect can result in improved tissue ingrowth,
this work utilized CMC as a porogen.43, 44 It was shown that in all groups a significant level
of tissue ingrowth within the scaffold was achieved.
The primary aim of this study was to determine if DNA encoding for transcription factors
delivered by bPEI-HA to a rat osteochondral defect via an OPF/CMC composite scaffold is
capable of improving tissue generation in an in vivo situation. To achieve this goal, first,
bilayered OPF/CMC hydrogels loaded with DNA encoding for eGFP complexed with bPEI-
HA as representative complexes were fabricated and their release kinetics studied in vitro to
characterize the system, as shown in the supplementary data. eGFP was selected as a
representative gene for use in in vitro studies due to its similar size to the plasmids used in
this study (4.7 kb vs. 4.7–5.8 kb for Runx2 and the Sox trio) and due to its use as an analog
in the literature.9, 45 Once release was characterized, implants were fabricated incorporating
bPEI-HA and DNA encoding for the SOX trio, DNA encoding for RUNX2, or a spatially
controlled combination of both and implanted into a rat osteochondral defect for 6 weeks, a
timepoint established in the literature. 46–48
The results presented above indicate that in this approach, the RUNX2 treatment group is
more capable than the SOX trio treatment group at achieving the desired tissue growth of
either bone or cartilage respectively. While the micro-CT analysis was unable to identify
significant differences between groups, RUNX2 containing groups did significantly better in
bone and general histological scoring than groups without RUNX2. This disparity between
tests is interesting, but the data produced by the histological sections is superior due to its
direct visualization of the morphology and integration of the generated tissue rather than
detection of mineralization within a pre-set volume.
The SOX trio only group proved incapable of generating significant cartilage growth within
the cartilage layer. It did, however score significantly better with respect to the distribution
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of the chondrocytes that did form, as seen in Figure 4e. This could indicate that the SOX trio
is having an effect on the target cells. The most probable reason for this disparity in
appropriate tissue generation is the inherent burst release associated with this system.
Previous work has shown that subchondral bone growth is necessary to support cartilage
growth.49 If it is assumed that the bioactive factors in this system are released quickly, the
DNA encoding for the SOX trio attempted to grow cartilage in this situation without the
mechanical support of subchondral bone. It is possible that in future work, if release of the
cartilage treatment factors was delayed, that more complete cartilage healing could be
observed.
It was found that combination therapy consisting of RUNX2 and SOX trio resulted in
greater tissue filling, implant degradation, and bone generation and quality. Several previous
studies have found that the combination of RUNX2 and the SOX trio results in negative
bone and cartilage regrowth, and it has been shown that they can counteract each other’s
action.20, 21 In fact, if they were transfecting the same cells, it would be expected from
previous work that the SOX trio would be dominant.22 As for the lack of interaction, we
hypothesize the spatial aspect of the loading excluded the infiltrated cells from being
transfected with both transcription factors. Because the bPEI-HA/DNA complexes were
entrapped in the OPF mesh network at the time of composite scaffold fabrication and
implantation, the two DNA treatments were kept separate. Once implanted, the natural
confines of the defect could limit diffusion of the complexes and the ability of RUNX2 and
the SOX trio to interact.
One potential explanation for the faster implant degradation and tissue ingrowth in the
combination treatment group could be the presence and amount of bPEI-HA in the defect. In
combination treatment groups, more bPEI-HA was present because of the bilayered loading.
OPF degrades via hydrolysis and the incorporation of an acid into the system accelerates the
rate of this hydrolysis.50 The faster degradation of the hydrogel would allow more space for
cellular infiltration and allow more cells to receive treatment with RUNX2 before the
complexes were released and cleared from the defect. It is important to note here though that
the degradation effects supplied by the bPEI-HA cannot be solely responsible for the tissue
growth observed as the SOX trio and RUNX2 groups showed significant differences in
tissue type and quality while incorporating identical amounts of bPEI-HA.
The primary limitation of the current study is its scope and additional studies could be
considered to attempt to refine the general approach presented here. The most obvious
approach would involve creating a different composite scaffold capable of delaying release
from the chondrogenic layer until appropriate subchondral bone has been formed. With that
said, the research presented here has shown that DNA encoding transcription factors
delivered with bPEI-HA is capable of improving tissue healing in vivo. Additionally, spatial
loading of two different treatments in a hydrogel scaffold is superior in this system to either
treatment alone and improves tissue ingrowth and implant degradation.
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The experiments described above show the potential of a bilayered approach in a rat
osteochondral defect. Spatial design and loading of the described implants resulted in
measurable improvements in overall tissue generation and quality, especially in the bone
layer. This improvement in healing is especially true when a combination of the SOX trio
and RUNX2 are used, though the inclusion of DNA encoding for RUNX2 also had a
significant effect on tissue growth. The results here demonstrate the ability to apply
polymeric gene therapy and transcription factors in vivo directly without implanting
transfected or transduced cells and in spatial combination with each other in an
osteochondral defect.
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Average percent bone generation identified through micro-CT. Error bars represent the
standard deviation of each group for n=8.
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Overall defect histological analysis where (a) corresponds to percent filling with new tissue
score and (b) corresponds to percent implant degradation. 0, 1, 2, and 3 correspond to
histology scores described in Table 2. Groups indicated by a “*” are statistically different
from all other groups while groups connected by lines and a “**” are significantly different
from each other.
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Bone tissue histological analysis where (a) corresponds to filling with new bone, (b)
corresponds to subchondral bone morphology, and (c) corresponds to bone bonding with
surrounding tissue. 0, 1, 2, 3, and 4 correspond to histology scores described in Table 2.
Groups indicated by a “*” are statistically different from all other groups while groups
connected by lines and a “**” are significantly different from each other.
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Cartilage tissue histological analysis where (a) corresponds to the morphology of the new
surface tissue, (b) is the morphology of the generated cartilage, (c) is the thickness of new
cartilage, (d) is the joint surface regularity, (e) is the chondrocyte distribution, (f) is the
chondrocyte cellularity, (g) is the safranin O staining, and (h) is the quality of the
surrounding cartilage. 0, 1, 2, 3, and 4 correspond to histology scores described in Table 2.
Groups indicated by a “*” are statistically different from all other groups while groups
connected by lines and a “**” are significantly different from each other.
Needham et al. Page 16














Representative histological sections of osteochondral tissue formation after 6 weeks of
implantation of composite scaffolds in the Combined treatment group which had bPEI-HA
and DNA encoding for the SOX trio in the top layer and RUNX2 in the bottom layer.
Sections were stained with (a) Safranin-O/Fast Green and (b) hematoxylin and eosin (H&E).
Scale bars = 500 μm. Magnified images indicate (c) a thick layer with a mixture of
fibrocartilage (FC) and mostly hyaline cartilage (C) and (d) underlying regenerated
subchondral cortical bone (CB) and near complete degradation of the composite scaffold.
Boxed regions are shown in higher magnification with scale bars = 250 μm.
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Representative histological sections of osteochondral tissue formation after 6 weeks of
implantation of composite scaffolds in the RUNX2 treatment group which had bPEI-HA and
DNA encoding for RUNX2 in the bottom layer. Sections were stained with (a) Safranin-O/
Fast Green and (b) hematoxylin and eosin (H&E). Scale bars = 500 μm. Images with higher
magnification indicate (b) regions of fibrocartilage (FC) with little safranin-o staining and
(c) regions with remaining hydrogel (H) indicated by voids in contact with newly formed
cortical bone tissue (CB).
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Representative histological sections of osteochondral tissue formation after 6 weeks of
implantation of composite scaffolds in the SOX trio treatment group which had bPEI-HA
and DNA encoding for the SOX trio in the top layer. Sections were stained with (a)
Safranin-O/Fast Green and (b) hematoxylin and eosin (H&E). Scale bars = 500 μm. Images
with higher magnification indicate (c) regions with very thin surface (TS), fibrous tissue
(FT) and some little fibrocartilage with minor safranin-o staining (FC) and (d) subchondral
regions with significant hydrogel remaining (H) and poor bone regeneration with fibrous
tissue present (FT).
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Representative histological sections of osteochondral tissue formation after 6 weeks of
implantation of composite scaffolds in the Empty hydrogel treatment group which had no
incorporated bPEI-HA/DNA complexes. Sections were stained with (a) Safranin-O/Fast
Green and (b) hematoxylin and eosin (H&E). Scale bars = 500 μm. Images with higher
magnification indicate regions with (c) a thin chondral layer (TS) made of fibrous tissue
(FT) and some fibrocartilage (FC) and (d) regions within the subchondral bone layer with
significant hydrogel remaining (H) with ingrowing fibrous tissue (FT).
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Table 1
In vivo experimental groups for rat osteochondral defect implantation.
Group Top (Chondrogenic) Layer Bottom (Osteogenic) Layer Purpose
Empty OPF only OPF only Scaffold control
SOX Trio bPEI-HA/SOX trio complexes OPF only Elucidate the effects of SOX trio alone
RUNX2 OPF only bPEI-HA/RUNX2 complexes Elucidate the effects of RUNX2 alone
Combined bPEI-HA/SOX trio complexes bPEI-HA/RUNX2 complexes Show potential interactions between SOX trio and RUNX2
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Table 2
Evaluation parameters for osteochondral defects37–40
Overall Defect Evaluation



















Mostly trabecular bone 4
Mostly compact bone 3
Mostly cartilage 2
Mostly fibrous tissue 1
Only fibrous tissue or no tissue 0
Extent of New Bone Bonding with Adjacent Bone
Complete on both edges 3
Complete on one edge 2
Partial on both edges 1
No continuity on either edge 0
Chondral Tissue Evaluation
Morphology of New Surface Tissue
Exclusively Articular Cartilage 4
Mainly Hyaline Cartilage 3
Fibrocartilage (spherical morphology in >75% of cells) 2
Mostly Fibrous Tissue (spherical morphology in <75% cells) 1
No tissue 0
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Morphology of New Cartilage
Exclusively Articular Cartilage 3
Mainly Hyaline Cartilage 2
Mainly Fibrocartilage 1
Only Fibrous Tissue/ No Tissue 0
Thickness of New Cartilage
Similar to surrounding cartilage 3
Greater than surrounding cartilage 2
Less than surrounding cartilage 1
No cartilage 0
Joint Surface Regularity
Smooth, intact surface 3
Surface fissures (<25% new surface thickness) 2
Deep fissures (25–99% new surface thickness) 1





Individual or disorganized cells 0
Chondrocyte Cellularity





Similar staining intensity 4
Stronger Staining intensity 3
Moderate staining intensity 2
Poor staining intensity 1
Little or no staining intensity 0
Chondrocyte and GAG Content of Adjacent Cartilage
Normal cellularity with normal GAG content 3
Normal cellularity with moderate GAG content 2
Clearly less cells with poor GAG content 1
Few cells with little or no GAGs or no cartilage 0
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